Pharmaxis to raise further funds
By Renate Krelle
Tuesday, 02 November, 2004
Tuesday, 02 November, 2004
Following its recent announcement of a successful Phase III trial of the successful completion of a Phase III clinical trial for its asthma diagnostic and treatment management tool Aridol, Sydney's Pharmaxis (ASX:PXS) has entered a trading halt -- to be lifted tomorrow morning -- pending the announcement of details of a placement and share purchase plan.
The company will conduct the placement via a bookbuild.
Related News
Quitting smoking increases life expectancy even for seniors
Although the benefits of quitting smoking diminish with age, there are still substantial gains...
Stem cell transplants treat blindness in mini pigs
Scientists have successfully transplanted retinas made from stem cells into blind mini pigs,...
Sugary drinks raise cardiovascular disease risk, but occasional sweets don't
Although higher sugar intake raises your risk of certain cardiovascular diseases, consuming sweet...
